Get the Stockscreener App
6.64
2.15%
0.14
After Hours:
6.61
-0.03
-0.45%
Precision Biosciences Inc stock is traded at $6.64, with a volume of 564.12K.
It is up +2.15% in the last 24 hours and up +42.18% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$6.50
Open:
$6.56
24h Volume:
564.12K
Relative Volume:
5.12
Market Cap:
$78.27M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-10.06
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
+12.93%
1M Performance:
+42.18%
6M Performance:
+32.53%
1Y Performance:
-26.30%
1-Day Range:
$6.1902
$6.87
1-Week Range:
$5.25
$6.87
52-Week Range:
$3.61
$9.20
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.64 | 68.95M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Is Precision BioSciences Inc. stock gaining market sharePortfolio Performance Report & AI Forecasted Entry/Exit Points - newser.com
Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last? - Yahoo Finance
Is Precision BioSciences Inc. meeting your algorithmic filter criteriaWeekly Investment Summary & Growth Oriented Trade Recommendations - newser.com
Is Precision BioSciences Inc. (PBS0) stock a top dividend aristocrat candidateLayoff News & Daily Growth Stock Investment Tips - newser.com
Is Precision BioSciences Inc. reversing from oversold territory2025 Trading Volume Trends & Expert Approved Momentum Trade Ideas - newser.com
Automated trading signals detected on Precision BioSciences Inc.Quarterly Investment Review & Weekly Breakout Stock Alerts - newser.com
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025 - BioSpace
Precision BioSciences announces late-breaking oral presentation for PBGENE-HBV at AASLD The Liver Meeting 2025 - MarketScreener
Precision Biosciences Announces Late-Breaking Oral Presentation For Pbgene-Hbv At Aasld The Liver Meeting® 2025 - TradingView
Regression analysis insights on Precision BioSciences Inc. performanceJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
Can a trend reversal in Precision BioSciences Inc. lead to recoveryJobs Report & Risk Controlled Swing Alerts - newser.com
Will a bounce in Precision BioSciences Inc. offer an exitWeekly Profit Report & Community Verified Trade Signals - newser.com
How Precision BioSciences Inc. stock trades during market volatilityShare Buyback & Safe Entry Point Alerts - newser.com
Has Precision BioSciences Inc. formed a bullish divergenceRate Cut & Consistent Growth Stock Picks - newser.com
Can Precision BioSciences Inc. stock resist market sell offsMarket Performance Summary & Real-Time Stock Entry Alerts - newser.com
Why Precision BioSciences Inc. stock attracts high net worth investors2025 Big Picture & Safe Entry Zone Identification - newser.com
Is Precision BioSciences Inc. (PBS0) stock undervalued by metricsMarket Weekly Review & Fast Entry High Yield Stock Tips - newser.com
Precision BioSciences Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Precision BioSciences Stock Surges on Gene-Editing Breakthroughs () - aktiencheck.de
Key metrics from Precision BioSciences Inc.’s quarterly dataTrade Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
What high frequency data says about Precision BioSciences Inc.July 2025 Opening Moves & High Conviction Buy Zone Alerts - newser.com
Will Precision BioSciences Inc. stock gain from lower inflationPortfolio Value Report & Fast Moving Stock Trade Plans - newser.com
News impact scoring models applied to Precision BioSciences Inc.IPO Watch & Free Technical Pattern Based Buy Signals - newser.com
Using RSI to spot recovery in Precision BioSciences Inc.Market Movement Recap & AI Forecasted Entry and Exit Points - newser.com
Will Precision BioSciences Inc. stock recover faster than marketTrade Ideas & Weekly Hot Stock Watchlists - newser.com
What moving averages say about Precision BioSciences Inc.July 2025 Fed Impact & Expert Approved Momentum Trade Ideas - newser.com
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for - PharmiWeb.com
Precision BioSciences (DTIL) Showcases Genomic Advances with ARC - GuruFocus
Precision BioSciences publishes research on ARCUS gene editing platform By Investing.com - Investing.com Canada
Relative strength of Precision BioSciences Inc. in sector analysisWall Street Watch & Community Verified Swing Trade Signals - newser.com
Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases - The AI Journal
Best data tools to analyze Precision BioSciences Inc. stockMarket Risk Analysis & Weekly High Potential Alerts - newser.com
Does Precision BioSciences Inc. qualify in momentum factor screeningWeekly Trade Review & Risk Managed Investment Entry Signals - newser.com
Why retail investors pile into Precision BioSciences Inc. stock2025 Market Overview & Reliable Volume Spike Alerts - newser.com
Precision BioSciences (NASDAQ:DTIL) Earns "Sell (E+)" Rating from Weiss Ratings - MarketBeat
Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial - BioSpace
Precision Biosciences, Inc. Announces Opening of First Clinical Trial Site in U.S. for Eliminate-B Trial - MarketScreener
Precision BioSciences (DTIL) Commences U.S. Clinical Trial for P - GuruFocus
Can Precision BioSciences Inc. (PBS0) stock hold up in economic slowdownPortfolio Risk Report & Reliable Price Action Trade Plans - newser.com
What momentum indicators show for Precision BioSciences Inc. stockOptions Play & Verified Swing Trading Watchlist - newser.com
Order flow analysis tools used on Precision BioSciences Inc.Weekly Gains Report & Fast Exit Strategy with Risk Control - newser.com
Why Precision BioSciences Inc. stock is rated strong buyTrade Risk Assessment & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-10-05 04:45:59 - newser.com
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brown Melinda | Director |
Sep 22 '25 |
Buy |
4.89 |
1,400 |
6,846 |
21,965 |
| Kelly John Alexander | Chief Financial Officer |
Jul 03 '25 |
Sale |
4.26 |
14,827 |
63,163 |
73,485 |
2.96%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):